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Objective: The objective of this study was to collect and critically analyze the current evidence on the modalities and
results of treatment of descending thoracic aortic surgical graft (SG) and endograft (EG) infection, which represents a rare
but dramatic complication after both surgical and endovascular aortic repair.
Methods: A comprehensive electronic health database search (PubMed/MEDLINE, Scopus, Google Scholar, and the
Cochrane Library) identified all articles that were published up to October 2017 reporting on thoracic aortic SG or EG
infection. Observational studies, multicenter reports, single-center series and case reports, case-control studies, and
guidelines were considered eligible if reporting specific results of treatment of descending thoracic aortic SG or EG
infection. Comparisons of patients presenting with SG or EG infection and between invasive and conservative treatment
were performed. Odds ratio (OR) meta-analyses were run when comparative data were available.
Results: Forty-three studies reporting on 233 patients with infected SG (49) or EG (184) were included. Four were
multicenter studies including 107 patients, all with EG infection, associated with a fistula in 91% of cases, with a reported
overall survival at 2 years of 16% to 39%. The remaining 39 single-center studies included 49 patients with SG infection
and 77 with EG infection. Association with aortoesophageal fistula was significantly more common with EG (60% vs 31%;
P ¼ .01). In addition, time interval from index procedure to infection was significantly shorter with EG (17 6 21 months vs
32 6 61 months; P ¼ .03). Meta-analysis showed a trend of increased 1-year mortality in patients with SG infection
compared with EG infection (pooled OR, 3.6; 95% confidence interval, 0.9-14.7; P ¼ .073). Surgical management with
infected graft explantation was associated with a trend toward lower 1-year mortality compared with graft preservation
(pooled OR, 0.3; 95% confidence interval, 0.1-1.0; P ¼ .056).
Conclusions: Thoracic aortic EG infection is likely to occur more frequently in association with aortoesophageal fistulas
and in a shorter time compared with SG infection. Survival is poor in both groups, especially in patients with SG infection.
Surgical treatment with graft explantation seems to be the preferable choice in fit patients. (J Vasc Surg 2019;69:1941-51.)
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fistula; Respiratory fistulaVascular prosthetic infection is a serious and often fatal
event; moreover, infection of an aortic surgical graft (SG)
or endograft (EG) previously implanted at the descend-
ing thoracic aortic level is considered one of the most
feared complications of modern vascular surgery.1 In
the last decades, the number of thoracic aortic
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have been observed more and more frequently, affecting
1% to 6 % of patients and entailing up to 75% mortality
rates even when recognized and treated.1
Nevertheless, the evidence is poor and consensus
documents are lacking in regard to the incidence, the
clinical features, the therapeutic options, and above all
the clinical outcome of this disease. The aim of this study
was to collect and critically analyze the published evi-
dence on the management and outcome of treatment
of prosthetic infection after previous repair of the
descending thoracic aorta to compare mortality of
patients presenting with SG or EG infection and of
patients managed conservatively or surgically.METHODS
Study design and search strategies. The review con-
formed to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statement standards.2 An
extensive electronic health database search was under-
taken to identify all the articles that were published1941
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June 2019before November 2017 reporting on SG and EG infections
after surgical repair or endovascular repair of thoracic or
thoracoabdominal aortic disease.
The following electronic bibliographic sources were
searched: PubMed/MEDLINE, Scopus, Google Scholar,
and the Cochrane Library. Search strategies included
MESH terms and keywords: (“aorta, thoracic”[MeSHTerms]
OR (“aorta”[All Fields] AND “thoracic”[All Fields]) OR
“thoracic aorta”[All Fields]) AND (“infection”[MeSH Terms]
OR “infection”[All Fields]) OR (“thoracic”[All Fields] AND
“Stent-Graft”[All Fields]) AND (“infection”[MeSH Terms] OR
“infection”[All Fields]) OR (“thoracic”[All Fields] AND “aor-
ta”[All Fields]) OR “graft”[All Fields] OR “Stent-Graft”[All
Fields] AND “infection”[All Fields] OR (“graft”[All Fields]
AND “infection”[All Fields]) OR “aortoesophageal”[All
Fields] AND (“fistula”[MeSH Terms] OR “fistula”[All Fields])
OR “aorto-oesophageal”[All Fields] AND (“fistula”[MeSH
Terms] OR “fistula”[All Fields]) OR “aortobronchial”[All
Fields] AND (“fistula”[MeSH Terms] OR “fistula”[All Fields]).
In addition, the reference lists of all retrieved articles
were examined for further relevant studies. The last
search was run in October 2017. Articles in languages
other than English were excluded.
Eligibility criteria and study selection. Initial study
selection and systematic review inclusion and exclusion
were performed by two authors (A.G., D.L.) on the basis
of the following eligibility criteria.
Observational studies, multicenter reports, single-center
series and case reports, case-control studies, and guide-
lines were included in the review analysis. No randomized
clinical trial was found covering this topic. Articles report-
ing on descending thoracic EG infection in patients with
initial associated supra-aortic trunk debranching (ie, prox-
imal landing zone 1 or zone 2) were included.
Articles reporting only on primary aortic infections (eg,
mycotic aneurysm, infectious aortitis, primary aortoeso-
phageal fistula [AEF] or aortobronchial fistula [ABF]),
even if affected patients were treated with surgical or
endovascular repair, were excluded. Papers limited to
graft infection of the ascending aorta, of the arch, or of
the infrarenal aorta and papers expressing general princi-
ples of vascular graft infection did not meet our eligibility
criteria. Articles failing to provide mortality data specif-
ically related to patients with descending thoracic or
thoracoabdominal aortic graft infection (eg, reporting
only about diagnostic modalities or mixing results of
abdominal and thoracic infections) were excluded.
When multiple publications on the same patient sample
were identified or study populations overlapped, only the
latest report was included unless the reported outcomes
were mutually exclusive.
Data extraction and study quality assessment. Each
study (full-text article) was reviewed by two independent
reviewers (A.K., A.G.), and the following data were
extracted and inserted in a precompiled electronicdatabase sheet: number of patients, baseline demo-
graphics, type of index procedure (surgical or endovascu-
lar), indication for index procedure, time interval to
infection diagnosis, clinical presentation, type of man-
agement, perioperative mortality, and mortality at
follow-up. If necessary, the article’s corresponding
author was contacted to confirm or to clarify specific
information.
The quality of evidence was assessed at the individual
study level by two authors (A.K., D.L.; Supplementary
Table, online only).
Summary process and results reporting. Because of
the possible overlap of populations of patients with
single-center reports, analysis of the results of multi-
center studies was performed separately, reporting
results (including follow-up survival) as described in the
original articles and avoiding summary measures and
comparative analysis.
For single-center reports, results were reported summa-
rizing (mean and proportions) available data extracted
by each study, according to the type of infected graft
(SG vs EG). Pooled mortality rate was reported at
30 days, 1 year, and 5 years.
Meta-analysis was performed including only observa-
tional studies reporting results of direct comparison
between given subgroups of patients (see Statistical
Analysis). For all meta-analyses, the primary end point
was considered the overall mortality rate at 1 year.
Statistical analysis. Standard descriptive statistics were
reported as numbers and percentages (categorical
variables) or mean and range (continuous variables).
Variables’ distribution was tested for normality by using
the D’Agostino-Pearson test. Comparisons between
patients presenting with SG infection or with EG infec-
tion were performed using two-tailed t-test for nor-
mally distributed continuous variables, Mann-Whitney
test for non-normally distributed continuous variables,
and Fisher exact test for categorical variables.
Three odds ratio (OR) meta-analyses of all eligible series
in accordance with the recommendations of the Meta-
analysis of Observational Studies in Epidemiology group3
were performed: SG infection vs EG infection; conserva-
tive medical treatment vs surgical (any kind) treatment;
and infected graft explantation vs preservation (consid-
ering only surgically treated patients). Pooled ORs were
initially calculated using a fixed-effect model and
reported as forest plots. Heterogeneity of included
studies was assessed using the I2 statistics.4 When
heterogeneity was considered high, ORs calculated
under the random-effects model were preferred.
Standard descriptive and comparison statistics were
run using Prism 7 statistical software (GraphPad
Software, Inc, La Jolla, Calif). The meta-analyses were
performed with MedCalc statistical software, version
17.9.7 (MedCalc Software, Ostend, Belgium).
Fig 1. Flow chart of studies identified and finally included in the review analysis.
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The initial literature search identified 1657 records, of
which239wereduplicates, andanother 1200wereconsid-
ered irrelevant after exclusion criteria application at the ti-
tle or abstract level. Among the remaining 218 articles
assessed for eligibility, 175 were excluded because of their
study design (including 4 systematic reviews/meta-
analyses summarizing the results of papers already indi-
vidually evaluated and 10 papers reporting only results of
diagnostic imaging) or because they reported insufficient
data on study outcomes. Finally, 43 studies (the first one
published in June 1999 and the last one in October 2017)
reporting on 233 patients with infected SG (12 studies, 49
patients) or infected EG (31 studies, 184 patients) were
included in thequalitative andquantitative analysis (Fig 1).
Multicenter reports. Among included articles, four
were based on large, multicenter retrospective series5-8
including 107 patients. All of these reported only data
of patients with thoracic EG infection. No articlesproviding multicenter reports on thoracic SG infection
were found in the literature. Analysis of results of multi-
center studies is summarized in Table I. Three studies
reported the incidence and outcome of AEF and ABF
after thoracic endovascular aortic repair (TEVAR)5,7,8; the
fourth study reported the incidence and outcome of EG
infection after both endovascular aneurysm repair
(EVAR) and TEVAR.6 The mean age of considered
patients was 70 years, and the male-female ratio was 3:1.
The indication for primary TEVAR, when reported, was
an atherosclerotic aneurysm in 69% of cases. The type
of infected EG was reported in 60 of 107 cases, of which
42 had polyethylene terephthalate (PET)-based fabric
and 18 had expanded polytetrafluoroethylene-based
fabric. Specific graft models were Valiant in 2 cases (Med-
tronic, Santa Rosa, Calif), Talent in 11 cases (Medtronic),
TAG in 18 cases (W. L. Gore & Associates, Flagstaff, Ariz),
Zenith TX1 in 2 cases (Cook Medical, Bloomington, Ind),
Zenith TX2 in 8 cases (Cook Medical), Endofit in 3 cases
(Endomed, Phoenix, Ariz), Relay in 5 cases (Bolton
Table I. Demographics, indication for index procedure, timing of infection diagnosis, clinical presentation, management
strategies, and outcome of 107 patients described in multicenter case series of infections after thoracic endovascular aortic
repair (TEVAR)
Chiesa et al,5 2010 Smeds et al,6 2016 Czerny et al,7 2014 Czerny et al,8 2015 Total
No. of patients 19 26 36 26 107
Age, years 73.8 6 7.1 68 69 (56-75) 70 (60-77)
Male 16 (84) 20 (77) 27 (75) 17 (65) 80 (75)
Indication for index procedure
Atherosclerotic aneurysm 13 (68) e 28 (77) 15 (58) 56 (69)
Dissection, PAU, IMH 2 (11) e e 6 (23) 8 (18)
Traumatic aortic injury 1 (5) e e 4 (15) 5 (11)
Mycotic, AEF, ABF e e 5 (14) e 5 (9)
Secondary pseudoaneurysm 3 (16) e e 1 (4) 4 (9)
Other e e 3 (8) e 3 (8)
Timing from index procedure
to diagnosis of infection, days
327 (e) 540 (5-2100) 90 (30-150) 310 (28-1065) 317 (5-2100)
Clinical presentation
Pain 1 (5) 17 (66) e 4 (15) 22 (31)
Fever or chills 11 (58) 17 (66) 29 (81) 7 (27) 64 (60)
Hematemesis or hemoptysis 13 (68) e 19 (53) 24 (92) 56 (69)
Shock 5 (26) e 8 (22) 6 (23) 19 (23)
Dyspnea 2 (10) e 2 (5) 7 (27) 11 (14)
AEF 13 (68) 12 (46) 36 (100) 0 (0) 61 (57)
ABF 5 (26) 0 (0) 0 (0) 26 (100) 31 (29)
AEF þ ABF 5 (26) 0 (0) 0 (0) 0 (0) 5 (5)
Managementa
Conservative 8 (42) 5 (19) 10 (28) 5 (19) 28 (26)
Fistula repair only 6 (32) e 13 (36) 4 (15) 23 (28)
Surgical þ fistula repair 1 (5) e 13 (36) 8 (31) 22 (27)
Surgical  fistula repair 1 (5) 21 (81) e e 22 (49)
Endo þ fistula repair 1 (5) e e 2 (8) 3 (7)
Endo  fistula repair 2 (11) e e 7 (27) 9 (20)
Outcome (survival)
Overall 16% (2-year) 29% (5-year) 28% (1-year) 39% (2-year)
Conservative 0% (30-day) 20% (1-year) 0% (1-year) e
Stent, esophageal only e e 17% (1-year) e
Open, esophageal only e e 43% (1-year) e
Open þ esophageal e e 46% (1-year) e
Open 27% (2-year) 29% (5-year) e e
ABF, Aortobronchial fistula; AEF, aortoesophageal fistula; IMH, intramural hematoma; PAU, penetrating aortic ulcer.
Categorical variables are presented as number (%). Continuous variables are presented as mean 6 standard deviation or median (interquartile range).
aConservative, medical treatment with or without minimally invasive additional procedures; Fistula repair only, esophageal or respiratory fistula repair,
without associated aortic repair; Surgical þ fistula repair, surgical open aortic repair associated with additional maneuvers to repair the fistula;
Surgical  fistula repair, surgical open aortic repair without additional maneuvers to repair the fistula; Endo þ fistula repair, endovascular aortic repair
(TEVAR) associated with additional maneuvers to repair the fistula; Endo  fistula repair, endovascular aortic repair (TEVAR) without additional
maneuvers to repair the fistula.
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Irvine, Calif).
In regard to possible etiologic factors of subsequent EG
infection, only Smeds et al6 (grouping together abdom-
inal and thoracic EVARs)mentioned an infectious compli-
cationduringor after the indexoperationoccurring in34%
of cases (urinary tract infection in 8%, groin infection in 7%,other unspecified infection in 19%). The same group
reported the occurrence of non-aorta-related secondary
procedures between the index operation and the diag-
nosis of infection in 69 patients (34%).
The mean time interval from index procedure to diag-
nosis of infection was 295 days (approximately
10 months). In 91% of reported patients, a fistula was
Journal of Vascular Surgery Kahlberg et al 1945
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or to confirm the diagnosis of aortic graft infection
were computed tomography scan in 80 cases and mag-
netic resonance imaging in one case. In case of associ-
ated fistula, the diagnosis was made by means of
esophagogastroduodenoscopy in 45 cases, aortography
in 2 cases, and esophageal transit study in 3 cases.
Only the study by Smeds et al6 specifically reported the
results of bacteriologic findings. Perioperative blood
cultures were positive in 63% of patients; intraoperative
cultures identified gram-positive organisms in 22%,
gram-negative organisms in 13%, and fungus in 5%. Intra-
operative cultures were polymicrobial in 35% (and this
was also considered a significant risk factor for morbidity
and mortality in patients managed surgically) and nega-
tive in 30% of cases.
A number of different strategies to treat EG infection
were reported (Table I). Smeds et al6 reported the type
of graft used for aortic reconstruction, as follows: a pros-
thetic graft in 16 cases (83% antibiotic soaked), a cryopre-
served allograft in 3 cases, and a femoropopliteal
neoaortoiliac system in 2 cases.
Reported postoperative complications after surgical
management of thoracic aortic graft infection included
respiratory failure in 15 patients, bleeding in 13, multior-
gan failure in 8, renal dysfunction in 5, mediastinitis in
4, and acute myocardial infarction in 3.
At a mean follow-up of 25 months (range, 1-60 months),
overall survivalwas 28% (30/107). Openaortic replacement
showeda survival of 27%at 2 years in one study andof 29%
at 5 years in another study. Surgical esophageal repair
showed a survival of 43% at 1 year when performed alone
and a survival of 46% at 1 year when associated with
open aortic repair. Conservative strategies were generally
associated with worse outcomes, showing a survival of
0% at 30 days in one study, 0% at 1 year in another study,
and 20% at 1 year in the last study. Similarly, esophageal
stenting alone showed a survival of 17% at 1 year.
Single-center reports. The remaining 39 articles
reported single-center experience: 11 were case series
with >5 patients,9-19 3 were case series with #5
patients,20-22 and 25 were case reports,23-47 with a total of
126 patients included in this analysis.
Among these, 49 patients presented with thoracic
aortic SG infection (41 descending thoracic grafts and 8
thoracoabdominal grafts), and 77 presented with
thoracic aortic EG infection. Among EG infection cases,
the type of infected EG was reported in 28 of 77 cases,
of which 20 had PET-based fabric and 8 had expanded
polytetrafluoroethylene-based fabric. Specific graft
models were Valiant in 9 cases (Medtronic), Talent in 7
cases (Medtronic), TAG in 7 cases (W. L. Gore), Zenith
TX2 in 2 cases (Cook Medical), Seal thoracic stent graft
in 1 case (S&G Biotech Inc, Seoul, Korea), Gianturco-
Rosch Z stent in 1 case (assembled at authors’ institution),and Bard custom-made thoracic stent graft in 1 case (C.R.
Bard, Tempe, AZ).
Demographics, data on clinical presentation, and out-
comes of the two groups are presented in Table II.
Eight papers mentioned some infectious complications
occurring during the perioperative period of the index
procedure. In particular, 7 papers9,27,28,37,39,40,45 (including
a total population of 17 patients) reported pulmonary
infection occurring in 9 patients, septicemia in 2, urinary
tract infection in 1, coagulopathy in 1, and early duodenal-
paraprosthetic fistula in 1 open thoracoabdominal repair
case. Another paper,14 reporting on 22 patients with EG
infection (but mixing abdominal and thoracic EVARs),
described 11 patients (50%) experiencing perioperative
septic complications.
Secondary vascular procedures occurring between the
index procedure and the diagnosis of infection were
reported in five cases, including one TEVAR after open
thoracoabdominal aortic repair due to proximal disease
progression, two cases of embolization of a type I endo-
leak, one bronchial stenting due to aneurysm sac
compression after TEVAR, and one emergent visceral
surgical debranching for thoracoabdominal disease pro-
gression. Nonvascular procedures were reported in five
patients, including two cases of pulmonary resection
associated with aortic replacement, one case of below-
knee amputation during the interval, one cholecystec-
tomy, and one case of multiple hospitalizations requiring
placement of central venous catheters.
In SG, the mean time interval from index procedure to
diagnosis of infection was 32.2 months, significantly
longer compared with EG (17.1 months; P ¼ .03). Associa-
tion with AEF was significantly less common with SG
than with EG (31% vs 60%, respectively; P ¼ .01). Symp-
toms at presentation, pain and fever or chills, were signif-
icantly more common with SG (73% vs 35% [P < .001]
and 84% vs 61% [P ¼ .02], respectively), whereas hema-
temesis was significantly more common with EG (42%
vs 19%; P ¼ .02). Imaging modalities used to make or to
confirm the original diagnosis of aortic graft infection
were computed tomography scan in 51 cases, fluoro-
deoxyglucose positron emission tomography in 3 cases,
and magnetic resonance imaging in 1 case. In case of
associated fistula, the diagnosis was made by means of
esophagogastroduodenoscopy in 29 cases, aortography
in 5 cases, and esophageal transit study in 4 cases.
Specific antimicrobial findings were reported in 18
papers (53 isolated microorganisms in 49 patients). In
almost all cases, findings were based on blood cultures.
Most commonly isolated micro-organisms were Staphy-
lococcus aureus (19 patients, methicillin resistant
[MRSA] in 7) and Streptococcus spp (12 patients); other
isolated microorganisms were Escherichia coli (5), Pseu-
domonas aeruginosa (4), Candida albicans (4), Entero-
coccus spp (3), Klebsiella spp (2), Lactobacillus spp (1),
Haemophilus influenzae (1), Serratia spp (1), and
Table II. Comparison of demographics, timing of infection diagnosis, clinical presentation, management, and mortality
between patients with previous thoracic open aortic repair and patients with previous thoracic endovascular aortic repair
(TEVAR), among the 126 patients described in single-center case series or case reports
SG infection, previous
open repair (n ¼ 49)
EG infection, previous
TEVAR, (n ¼ 77)
PAvailablea Positiveb %c Availablea Positiveb %c
Male sex 30 25 83 41 30 73 .39
Age, years, mean 6 SD 47 62.5 6 11.4 76 64.9 6 12.2 .17
Timing from index procedure,
months, mean 6 SD
31 32.2 6 61.1 52 17.1 6 21.1 .03
Clinical presentation
AEF 32 10 31 60 36 60 .01
ABF 32 4 13 60 11 18 .56
AEF þ ABF 32 0 0 60 1 2 1.0
Pain 37 27 73 48 17 35 <.001
Fever or chills 37 31 84 61 37 61 .02
Hematemesis 37 7 19 52 22 42 .02
Hemoptysis 37 6 16 52 8 15 1.0
Shock 37 4 11 52 8 15 .75
Dyspnea 24 0 0 46 1 2 1.0
Sepsis 24 2 8 55 6 11 1.0
Managementd
Conservative 49 1 2 77 14 18.2 .02
Fistula repair only 49 1 2 77 10 12.9 .06
Surgical þ fistula repair 49 e e 77 2 2.6 .52
Surgical  fistula repair 49 2 4.5 77 7 9.1 .48
Endo þ fistula repair 49 12 27 77 23 29.9 .69
Endo  fistula repair 49 25 52 77 16 20.8 .02
TEVAR/ open 49 6 12.5 77 5 6.5 .35
Mortality
30-day 48 16 33 73 19 26 .42
1-year 47 27 57 67 36 54 .71
5-year 34 28 82 52 42 81 1.0
ABF, Aortobronchial fistula; AEF, aortoesophageal fistula; EG, endograft; SD, standard deviation; SG, surgical graft.
Numbers in bold are considered statistically significant.
aThe number of patients for whom the specific information was available in the included studies.
bThe number of affected patients for each single item.
cPercentages of positive patients of the available ones.
dConservative, medical treatment with or without minimally invasive additional procedures; Fistula repair only, esophageal or respiratory fistula repair,
without associated aortic repair; Surgical þ fistula repair, surgical open aortic repair associated with additional maneuvers to repair the fistula;
Surgical  fistula repair, surgical open aortic repair without additional maneuvers to repair the fistula; Endo þ fistula repair, endovascular aortic repair
(TEVAR) associated with additional maneuvers to repair the fistula; Endo  fistula repair, endovascular aortic repair (TEVAR) without additional
maneuvers to repair the fistula; TEVAR/ open, endovascular aortic repair to obtain hemodynamic stability followed by open surgical aortic repair.
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patients with documented antimicrobial growth at cul-
ture was 14% (7/49), 5 of which were positive for MRSA.
For MRSA-positive patients, 30-day mortality was 71%;
for methicillin-sensitive S. aureus-positive patients, 9%;
and for Streptococcus-positive patients, 8%. No signifi-
cant difference in outcome was noted between patients
with isolation of a single agent and patients with polymi-
crobial isolation.
Conservative treatment, mainly represented by anti-
biotic therapy, sometimes associated with percutaneousdrainage of fluid collections or flushing, was performed
in 2% of patients with SG (1/49) and 17% with EG (13/77).
This approach resulted in a mortality rate of 100% at
30 days in the SG infection group and 38%, 75%, and
100% in the EG infection group at 30 days, 1 year, and
5 years, respectively.
In the remaining patients, different surgical strategies
were used, including aggressive open aortic repair with
or without associated fistula repair, TEVAR with or
without associated fistula repair, and esophageal or
bronchial-pulmonary repair alone. Seventy-four patients
Fig 2. Pooled odds ratio (OR) meta-analysis comparing 1-year mortality among patients with surgical graft (SG)
infection and patients with endograft (EG) infection. CI, Confidence interval.
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40 cases (antibiotic soaked in 15 cases), a cryopreserved
allograft in 22 cases, a xenopericardial tube graft in 9
cases, a silver-coated PET graft in 2 cases, and an autolo-
gous vein graft in 1 case.
Reported postoperative complications included respi-
ratory failure in 22 patients, persistent sepsis in 13, multi-
organ failure in 13, bleeding in 13, cardiac complications
in 7, renal dysfunction in 5, paraplegia in 5, mediastinitis
in 5, vocal cord paralysis in 3, esophageal leak in 2, wound
infection in 2, recurrent aortopulmonary fistula in 1,
encephalopathy in 1, and cholecystitis in 1.
Global 30-day, 1-year, and 5-year mortality was 33%,
57%, and 82% in patients with SG infection and 26%,
54%, and 81% in patients with EG infection, respectively.
Meta-analyses results. The OR meta-analysis of SG
infection vs EG infection included five comparative
studies (Fig 2). The statistical heterogeneity was low
(I2 ¼ 2%; P ¼ .38). Even if it was not statistically significant,
a slight tendency to increased overall mortality rate at
1 year was noted in patients with SG infection (pooled
OR, 3.6; 95% confidence interval [CI], 0.9-14.7; P ¼ .073).
The OR meta-analysis of conservative treatment vs sur-
gical treatment included five comparative studies (Fig 3).
The statistical heterogeneity was low (I2 ¼ 5%; P ¼ .37). No
significant difference in overall mortality rate at 1 year
was noted between conservative and surgical treatment
(pooled OR, 0.6; 95% CI, 0.1-2.3; P ¼ .425).
Finally, the OR meta-analysis of infected graft explan-
tation vs preservation included seven comparative
studies (Fig 4). The statistical heterogeneity was low
(I2 ¼ 0%; P ¼ .42). A slight trend toward lower mortality
rate at 1-year outcome was noted in patients with
infected graft explantation (pooled OR, 0.3; 95% CI,
0.1-1.0; P ¼ .056).DISCUSSION
Published scientific evidence on thoracic aortic pros-
thetic infection is definitely scarce. This is mainly due to
the following reasons:
d Relative rarity of this complication. The majority of
published papers are case reports or small series. This
is probably also a cause of underestimation because
of the lack of single-center reports by small centers
experiencing few cases and not reporting them.
d Frequent late occurrence. Several patients might
receive the diagnosis and treatment of infection years
later in a different center from the index procedure.
d Heterogeneity in clinical presentation. Reports are
often mixing elective and emergent cases, with or
without associated AEF or ABF fistula.
d Heterogeneity in treatment strategies. Published
papers usually include a number of different pharma-
cologic, surgical, and endovascular therapeutic
options. Surgical strategies and timing modalities are
mostly chosen according to the surgeon’s experience
and the patient’s condition.
Infection of a thoracic aortic prosthesis is, however, a
morbid condition, and mortality often exceeds 50%
and can be as high as 100% for untreated cases.5-8 There
are no prospective randomized trials concerning the
treatment options for this condition, and the presence
of many different variations makes it even more difficult
to draw sound conclusions that may apply to the individ-
ual case.
In this paper, we considered for analysis the original
studies that referred to cases with an SG or EG involve-
ment and not the reviews as a whole. However, a brief
discussion of these reviews is provided here.
In the last two decades, TEVAR has been gradually
replacing open intervention with surgical replacement
Fig 3. Pooled odds ratio (OR) meta-analysis comparing 1-year mortality among patients treated conservatively
and patients treated surgically (any kind of surgical treatment). CI, Confidence interval.
Fig 4. Pooled odds ratio (OR) meta-analysis comparing 1-year mortality among patients with infected graft
explantation and graft preservation. CI, Confidence interval.
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the lack of prospective randomized trials, TEVAR is
accepted as the treatment of choice for most cases of
thoracic aortic disease that have anatomic feasibility;
exceptions might apply mainly to patients with connec-
tive tissue diseases. Therefore, a relevant portion of the
most recent data available on thoracic aortic graft infec-
tion actually refers to EG.
Moulakakis et al48 in 2014 reviewed the literature for
graft infection after TEVAR. They analyzed 55 patients
treated with preservation of the EG and 41 with excision.
Preservation of the EG with antibiotic therapy alone was
shown not to be a durable option; their meta-analysis
showed a trend for better outcomes in patients with
EG excision. The authors found a trend for worse
outcomes in patients with fistulas. Moreover, there was
no difference whether the patients were treated with in
situ or extra-anatomic reconstructions.Our review identified 43 articles reporting on 49
patients with thoracic aortic SG infection and 184
patients with thoracic EG infection. Among these, four
were multicenter studies, all focused on EG infection,
associated with a fistula in 91% of cases. Patients pre-
sented with hematemesis or hemoptysis in 53% to 92%
of cases and shock in 22% to 26%. Management
included several different strategies that we may divide
into “purely conservative” (19%-42% of cases) and some-
what “operative” (58%-81%). The operative cases included
open aortic replacement, with or without associated
esophageal or bronchial repair; repeated TEVAR, with
or without associated esophageal or bronchial repair;
and esophageal or bronchial open repair or endoscopic
treatment (stenting) alone. Outcome reporting was
totally heterogeneous in these multicenter reports,
mainly represented by survival at different time points,
and not specifying results per single management
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Volume 69, Number 6strategy in most cases. Nevertheless, conservative treat-
ment was associated with the poorest survival (0%-20%
at 1 year), whereas operative treatment showed a survival
ranging from 27% to 39% at different follow-up points
(up to 5 years).
Among patients described in the 39 single-center
studies, the time interval between index procedure and
diagnosis of infection was shorter in patients with previ-
ous endografting than in patients with previous surgical
repair. This result may be explained by the typically
different cohort of patients treated with TEVAR
compared with surgically treated ones. In particular,
TEVAR is usually the preferred strategy for treatment of
aortic pseudoaneurysms and saccular aneurysms, espe-
cially in an emergency, and a proportion of these cases
may represent “undiagnosed” infected aneurysms or
pseudoaneurysms. Moreover, the enhanced medical
surveillance that is usually advised after TEVAR may
account for a significant reduction in the time needed
to diagnose infectious complications.
Patients with EG infection were also more frequently
reported to have an associated AEF than patients with
SG infection. Even if detailed causes of this process are
still unclear, this finding is consistent with a number of
studies confirming that both thoracic and abdominal
aortic endografting may be complicated by gastrointes-
tinal fistulization, at least at the same rate as after surgi-
cal treatment.5,7,49
This review of single-center published series and case
reports confirmed that clinical outcomes of thoracic
aortic prosthetic infections are poor, with overall survival
of 45% at 1 year and 19% at 5 years. Probably because of
the small number of cases, meta-analyses failed to reach
statistical significance in showing an undisputable differ-
ence in 1-year mortality between EG infection and SG
infection. However, a slight (nonsignificant) trend was
noted toward worse outcomes in case of SG infection
that may be explained by the higher surgical complexity
of “redo” interventions in case of previous open aortic sur-
gery compared with patients who experienced only
endovascular interventions, with presence of more
extensive adhesions and “frozen” chest. Similarly, in
comparing infected graft explantation vs graft preserva-
tion, the graft explantation strategy seemed to be associ-
ated with a better outcome, even if this result may be
biased by the small number of studies included and by
the low statistical power. Nonetheless, this finding is
consistent with the previous published evidence on
superiority of EG explantation vs preservation in patients
with post-TEVAR infections,48 probably reflecting the
inability of antibiotic therapy alone to eradicate infection
involving either a surgical or an endovascular aortic pros-
thetic graft.
We acknowledge some limitations of this review. The
heterogeneity of the included patients (infection of surgi-
cal or endovascular graft, presence or absence ofassociated fistula, conservative or surgical management)
makes it difficult to draw consistent conclusions from
pooling to drive clinical decision-making. However,
consideration should be given to the results presented
because they are at present the most comprehensive
data on a topic that is still not sufficiently addressed in
the literature. The decision to include a large number
of small studies, including case reports, is driven by the
rarity of this disease. This may account for publication
bias due to the plausible attitude of small centers to
report most “interesting” and “successful” cases. Also, a
time bias should be considered in comparing results of
SG infection with the more recent cases of EG infection.
Furthermore, a number of studies were excluded for
lacking or incomplete reporting.
CONCLUSIONS
This systematic review showed that thoracic aortic EG
infection presents some differences compared with SG
infection regarding frequency of associated aortoeso-
phageal fistulization, time interval between index pro-
cedure and diagnosis of infection, and symptoms at
presentation. Overall survival is poor in both groups, but
meta-analysis found a trend of worse outcome in
patients with SG infection. Even if treatment strategies
are various and depend on each center’s experience
and on specific patients’ conditions, the current evidence
probably seems to support surgical treatment with graft
explantation when it is feasible. However, these data are
so far too weak to justify changes in clinical practice, and
more comparative studies are needed to provide clinical
recommendations in the future.
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